<DOC>
	<DOCNO>NCT00605111</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial investigate efficacy safety biphasic insulin aspart 30 start insulin subject type 2 diabetes fail OAD therapy .</brief_summary>
	<brief_title>Efficacy Safety Biphasic Insulin Aspart 30 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes least 24 month BMI 18 30 kg/m2 Insulin naive subject OAD treatment max two OADs alone combine therapy HbA1c 712 % Type 1 diabetes Receipt investigational drug within last three month prior trial Current previous treatment thiazolidiones within last 6 month OAD treatment three OADs within last 4 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>